Commercial-stage biopharmaceutical company developing therapies for rare and serious diseases, including ARIKAYCE for refractory NTM lung infection and brensocatib for bronchiectasis.
Brensocatib FDA decision (bronchiectasis)
TPIP Phase 3 long-term data
The FDA granted priority review to Insmed's supplemental NDA for ARIKAYCE (amikacin liposome inhalation suspension) for the treatment of MAC lung disease, with a PDUFA target action date set for January 28, 2027.
Insmed's PAH drug shows long-term durability data supporting a $6B market opportunity.
Chair and Chief Executive Officer
Chief Financial Officer
Head of Clinical Development